CIK 0000882796 · Large accelerated filer
BIOCRYST PHARMACEUTICALS INC
Sign in to watch- Ticker
- BCRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 621413174
- Phone
- 919-859-1302
- Business address
- 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, 27703
- 3 Insider Initial Statement of Ownership
- 8-K/A Event Executive or director change
- 8-K Event Material agreement · Acquisition or sale completed · New debt or obligation · Regulation FD disclosure
- 8-K Event Results of operations · Regulation FD disclosure · Other events
- 3 Insider Initial Statement of Ownership
- 8-K Event Regulation FD disclosure
- 4 Shares withheld for taxes Chief Executive Officer gave up 61,793 shares (to pay taxes)
- 4 Planned sale Chief Legal Officer sold 21,773 shares at $7.65 ($166,563)
- 4 Option exercise President and CCO acquired 74,233 shares (option exercise)
- 144 Insider Sale of Securities
- 4 Gift Chief Executive Officer gave 20,000 shares (gift)
- 4 Grant or award President and CCO acquired 471,000 shares (grant or award)
- 4 Grant or award Chief Legal Officer acquired 121,700 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 121,700 shares (grant or award)
- EFFECT Other Notice of Effectiveness
- 424B3 Offering Prospectus
- 4 Shares withheld for taxes President and CCO gave up 8,181 shares (to pay taxes)
- 4 Planned sale Chief Legal Officer sold 21,210 shares at $7.65 ($162,257)
- 4 Shares withheld for taxes Chief Executive Officer gave up 27,368 shares (to pay taxes)
- CORRESP Other Correspondence Between Filers and SEC Staff
Page 4 of 99 · 1,967 filings